| FIALA, O., P. HOSEK, M. PESEK, J. FINEK, J. RACEK, T. BUCHLER, Alexandr POPRACH, Karel HEJDUK, Renata CHLOUPKOVÁ, O. SOREJS, M. ECKSTEINOVA, M. VITOVEC, K. CIZKOVA, R. KUCERA a O. TOPOLCAN. Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed. Online. Neoplasma. Bratislava: Slovenská akademie vied, 2017, roč. 64, č. 4, s. 605-610. ISSN 0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo_2017_416. [citováno 2024-04-24] |
Další formáty:
BibTeX
LaTeX
RIS
@article{1388308,
author = {Fiala, O. and Hosek, P. and Pesek, M. and Finek, J. and Racek, J. and Buchler, T. and Poprach, Alexandr and Hejduk, Karel and Chloupková, Renata and Sorejs, O. and Ecksteinova, M. and Vitovec, M. and Cizkova, K. and Kucera, R. and Topolcan, O.},
article_location = {Bratislava},
article_number = {4},
doi = {http://dx.doi.org/10.4149/neo_2017_416},
keywords = {C-reactive protein; lung cancer; NSCLC; chemotherapy; pemetrexed; prognosis},
language = {eng},
issn = {0028-2685},
journal = {Neoplasma},
title = {Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed},
volume = {64},
year = {2017}
}
TY - JOUR
ID - 1388308
AU - Fiala, O. - Hosek, P. - Pesek, M. - Finek, J. - Racek, J. - Buchler, T. - Poprach, Alexandr - Hejduk, Karel - Chloupková, Renata - Sorejs, O. - Ecksteinova, M. - Vitovec, M. - Cizkova, K. - Kucera, R. - Topolcan, O.
PY - 2017
TI - Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed
JF - Neoplasma
VL - 64
IS - 4
SP - 605-610
EP - 605-610
PB - Slovenská akademie vied
SN - 00282685
KW - C-reactive protein
KW - lung cancer
KW - NSCLC
KW - chemotherapy
KW - pemetrexed
KW - prognosis
N2 - Pemetrexed is an intravenously administered antifolate cytostatic agent targeting several folate-dependent enzymatic pathways, widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC). It has been previously demonstrated that the superiority of pemetrexed is limited to patients with non-squamous histology. Aside from the non-squamous histology, there is still no available molecular biomarker predicting treatment efficacy of pemetrexed-based chemotherapy. The aim of our retrospective study was to evaluate the association of baseline serum levels of C-reactive protein (CRP) with outcomes in a large cohort of patients with non-squamous NSCLC treated with pemetrexed. Clinical data of 325 patients were analysed. Serum samples were collected within one week before the initiation of treatment. The median progression-free (PFS) and overall survival (OS) for patients with high CRP was 2.1 and 9.5 compared to 4.2 and 20.5 months for those with normal CRP (p=0.002 and p<0.001, respectively). The multivariable Cox proportional hazards model revealed that serum CRP (HR=1.46, p=0.002) was significantly associated with PFS and also with OS (HR=1.95, p<0.001). In conclusion, the study results suggest that pretreatment serum CRP is associated with poor outcome of non-squamous NSCLC patients treated with pemetrexed.
ER -
FIALA, O., P. HOSEK, M. PESEK, J. FINEK, J. RACEK, T. BUCHLER, Alexandr POPRACH, Karel HEJDUK, Renata CHLOUPKOVÁ, O. SOREJS, M. ECKSTEINOVA, M. VITOVEC, K. CIZKOVA, R. KUCERA a O. TOPOLCAN. Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed. Online. \textit{Neoplasma}. Bratislava: Slovenská akademie vied, 2017, roč.~64, č.~4, s.~605-610. ISSN~0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo\_{}2017\_{}416. [citováno 2024-04-24]
|
